Immunotherapy with pembrolizumab deemed cost-effective for advanced melanoma in Hong Kong

(European Society for Medical Oncology) Immunotherapy with pembrolizumab has been deemed a cost-effective first line treatment for advanced melanoma patients in Hong Kong, researchers report at the ESMO Asia 2016 Congress in Singapore.